Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk
Safety (cardiac & more) In vitro landmark
AI-extracted · unverified · confirm at source
Ibogaine blocks hERG channels with IC₅₀ of 4 μM, overlapping therapeutic plasma concentrations (low μM range), providing first mechanistic evidence for ibogaine-induced QT prolongation and cardiac arrhythmia risk.
Dosing: IC₅₀ 3.9 μM — in vitro hERG patch-clamp; overlaps therapeutic plasma range (low μM) (not-applicable)
Safety data present: HERG
Contraindications: Pre-existing cardiac conditions, QT-prolonging medications